The prerequisite for obtaining marketing authorisation is an appropriate and robust data package that demonstrates a medicinal product’s quality and its efficacy and safety in the proposed indication. Pharmaceutical companies can face regulatory challenges during product development, especially in case of novel treatment modalities, new substances, or rare indications. To support the generation of the appropriate evidence and accelerate patient access to novel treatments, both the EMA and National Competent Authorities offer scientific advice, which allows companies to obtain guidance from a panel of experts regarding quality, nonclinical, clinical, or other aspects of their development strategy. This review provides regulatory background information on the scientific advice procedure in the EU for medical writers, who may become involved in the preparation of the pertaining briefing package.
Editor-in-Chief
Co-Editors
Managing Editor
Victoria White
Associate Editors
Section Editors
Biotechnology
Digital Communication
EMWA News
Gained in Translation
Getting Your Foot in the Door
Good Writing Practice
In the Bookstores
Manuscript Writing
Medical Communications/Writing for Patients
Medical Devices
My First Medical Writing
News from the EMA
Out on Our Own
Pharmacovigilance
Regulatory Matters
Regulatory Public Disclosure
Teaching Medical Writing
The Crofter: Sustainable Communications
Veterinary Writing
Editors Emeritus
Lay out Designer
Chris Monk